►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".
►►Very important notification on publication fee
Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.
Cancer Biology & Medicine is a peer-reviewed open-access journal published by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
Author Benefits
● Easy submission via online system
● Efficient and professional peer review
● Rapid pre-print online publication
● No charge for publication and open access
● International visibility-All full texts are free in PubMed Central
Announcements
Publication of the 3rd issue in 2019 |
|
In 3rd issue of 2019, a perspective from Prof. Binghui Li discussed Warburg effect and related proton homeostasis in proliferating cells. Prof Mo Li reviewed tissue specificity of DNA damage response and tumorigenesis. Prof. Yukun Cui focused on targeted intervention in malignancy. Prof. Masatoshi Makuuchi from Japan shared his insights and experience in precision surgery for primary liver cancer. . Application of nanotechnology in cancer immunotherapy is summarized in Prof. Ning Gu’s review.
Besides, two highly recommended original articles are as follows, “Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients” by Prof. Chengping Hu et al. and “Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China” by Wanqing Chen et al. Other researches involve molecular mechanisms and clinical treatment of melanoma, gastric cancer, lymphoma, breast cancer, and so on.
We hope the content of this issue will greatly benefit your research and clinical practice. Thank you for your attention and welcome to submit your work to Cancer Biology & Medicine.
|
|
| Posted: 2019-08-14 | |
NEW IMPACT FACTOR 4.467 |
|
According to the Journal Citation Reports (2019), the IMPACT FACTOR (2018) of Cancer Biology & Medicine is 4.467, locating in Q1 area of Medicine, Research & Experimental category (ranking 33/136) and Q2 area of Oncology category (ranking 66/229). |
|
| Posted: 2019-06-25 | |
| More Announcements... |
Lung Cancer Collection (2017-2019)
Table of Contents
Original Article
| Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer | |
| Yuxiang Wang, et al | 66-78 |
| Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study | |
| Yihui Du, et al. | 181-188 |
| Attenuated plasmodium sporozoite expressing MAGE-A3 induces antigen-specific CD8+ T cell response against lung cancer in mice | |
| Dong Zhou, et al | 288-298 |
| Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data | |
| Ashley M. Hopkins, et al | 341-349 |
| EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation | |
| Yang Chen, et al. | 39-51 |
| Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer | |
| Wuhao Huang, et al | 88-96 |
| Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy | |
| Ye Tian, et al. | 157-164 |
| Knockdown of long non-coding RNA LCPAT1 inhibits autophagy in lung cancer | |
| Xiao Yu, et al. | 228-237 |
| Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway | |
| Lianmei Zhao, et al | 400-414 |
| PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs | |
| Yuchen Bai, et al. | 434-442 |
| Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment | |
| Jing Wang, et al | 443-451 |
| Estimation of lung cancer burden in Australia, the Philippines, and Singapore: an evaluation of disability adjusted life years | |
| Suman Morampudi, et al. | 74-82 |
| Inhibition of IKK-NFκB pathway sensitizes lung cancer cell lines to radiation | |
| Avgi Tsolou, et al. | 293-301 |
Case Report
| Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report | |
| Ling Zhang, et al. | 178-181 |
| Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report | |
| Peng Wang, et al | 183-186 |
OUR FRIENDS
